Does ANGO pay a dividend and is it safe?

AngioDynamics Inc. (ANGO) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / ANGO / dividends

SENS (40) SGHT (39) DCTH (59) TCMD (67) ⌘ Pro Terminal →

AngioDynamics Inc. (ANGO) Dividend Safety Gauge & 10-Year DRIP Compounder

$11.76 -1.92% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $11.70

AngioDynamics Inc. (ANGO) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $504.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ANGO Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ANGO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, AngioDynamics Inc. (NASDAQ: ANGO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $11.76 (-1.92% 1D, market cap $504.2M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, ANGO ranks #565 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ANGO compare to SENS and SGHT in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), ANGO carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of 54.6%, and ROIC of -23.4%. By comparison, SENS (Senseonics Holdings Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $502.8M) and SGHT (Sight Sciences Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $513.4M). Among the 5-stock peer group, TCMD leads on earnings multiple (28.9x) while TCMD leads on capital efficiency (17.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ANGO?

▼

Per ANGO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-05-31, CIK 0001275187), AngioDynamics Inc. generated $320.2M in revenue (+9.5% YoY), -$36.7M in net income, and $508.0K in free cash flow against $269.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $11.70 (-0.54%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 0.2% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-9.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ANGO)Realized 20D OHLCV Swing Band: ±11.6%

Deterministic 5-Pillar Attribution (36/100 Composite)

🔍 WHY ANGO SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+10/20 pts (28% of score)

SEC XBRL FY 2025 (10-K): 0.2% FCF Margin ($508.0K FCF) & 54.6% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (28% of score)

Altman Z-Score 2.12 (WATCH ZONE (1.8–3.0)) • Piotroski F-Score 6/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$10.90+8.3% Next Q

Q2 (-2Q)

Grade E$11.81+3.8% Next Q

Q3 (-1Q)

Grade E$12.26-4.1% Next Q

Current

Grade D-$11.76-8.3% Hist 90D α

Trajectory: E (28) → D- (36)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ANGO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ANGO currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($14.04) and Max Pain ($12.35) forces dealer call-delta covering toward $17.10.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ANGO• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ANGO Beats Next Quarter EPS Consensus (Nov 29, 2026) & Holds Above 200D SMA”

YES 36%NO 64%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,573

Est. Year-10 Shareholder Yield: $105/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.2K

Yr 2

$11.8K

Yr 3

$12.5K

Yr 4

$13.3K

Yr 5

$14.0K

Yr 6

$14.8K

Yr 7

$15.7K

Yr 8

$16.6K

Yr 9

$17.6K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ANGO)

✓Walkthrough of ANGO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ANGO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +7.10%📐 HORIZONTAL RANGE

2026-11-03O $12.35H $12.35L $11.76C $11.76VOL 475.8K

RES: $17.74SUP: $10.44SMA50: $14.04SMA200: $12.49

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ANGO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ANGO Butterfly Map → + Track ANGO →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +9.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ANGO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ANGO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ANGO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ANGO)

Health Care Rank #565 of 1015 ⚔️ SENS vs ANGO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ANGO vs. SENS, SGHT, DCTH, TCMD)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, AngioDynamics Inc. (ANGO) ranks #565 by composite RQD confidence (36/100, grade D-) and #440 by equity capitalization ($504.2M). Within this direct 5-issuer industry benchmark cohort, TCMD leads on earnings valuation at 28.9x trailing P/E, while TCMD leads on capital efficiency and profitability with 17.1% ROIC and 75.9% gross margin. TCMD currently holds the highest overall quantitative score in the immediate peer group at 67/100 (C+) compared with ANGO at 36/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ANGO ACTIVE AngioDynamics Inc.	D-	36/100	—	54.6%	-23.4%	-1.92%	$504.2M	Benchmark Subject
SENS Senseonics Holdings Inc.	D-	40/100	—	44.7%	-35.0%	-5.57%	$502.8M	/sens-vs-ango →
SGHT Sight Sciences Inc.	D-	39/100	—	86.2%	-35.0%	-1.82%	$513.4M	/sght-vs-ango →
DCTH Delcath Systems Inc.	C-	59/100	—	86.2%	0.8%	+1.78%	$487.2M	/dcth-vs-ango →
TCMD Tactile Systems Technology Inc.	C+	67/100	28.9x	75.9%	17.1%	-0.74%	$521.9M	/tcmd-vs-ango →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-05-31 • CIK 0001275187 ↗

In its most recent audited fiscal period (FY2025, filed 2026-05-31), AngioDynamics Inc. (ANGO) reported GAAP revenue of $320.2M (+9.5% vs. FY2024 revenue of $292.5M , and +5.4% cumulative change since FY2023) , GAAP net income of -$36.7M, operating cash flow of $3.1M, and free cash flow of $508.0K (+103.5% YoY). On the balance sheet, ANGO closed FY2025 with $269.7M in total assets against $0 in total debt (Altman Z-Score: 2.12, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2026-05-31	$320.2M	-$36.7M	$3.1M	$508.0K	$269.7M	—
FY2024 (FY)	2025-05-31	$292.5M	-$34.0M	-$10.1M	-$14.6M	$291.6M	—
FY2023 (FY)	2024-05-31	$303.9M	-$184.3M	-$28.2M	-$28.2M	—	—

3. ANGO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ANGO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ANGO compare to SENS and SGHT in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ANGO?

Where is ANGO trading relative to its 50-day, 200-day, and 52-week technical levels?

ANGO last traded at $11.76 (-1.92% on volume of 456,653 shares), positioning the stock -16.24% below its 50-day simple moving average ($14.04) and -5.84% below its 200-day simple moving average ($12.49). Across its 52-week range of $9.39 to $16.29, ANGO sits at the 34.3% percentile with a 14-day RSI of 40.8 (NEUTRAL RANGE) and an implied next-earnings move of ±11.6% ($10.40 to $13.12).

Direct Sub-Reports: ANGO RQD Cockpit ANGO 12M Forecast ANGO Earnings & Move ANGO Dividends & DRIP ANGO Insiders & 13F ANGO Whale Options ANGO Profit Sankey ANGO News & Why

ROARABLE RATING BRIEF • RQD 36/100 (D-) ✓ SEC XBRL & RQD VERIFIED

ANGO — AngioDynamics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2026-05-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

AngioDynamics Inc. (ANGO) earns a live Roarable RQD composite score of 36/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $11.76 (-1.92% 1D, market capitalization $504.2M).

Fundamental Cash Engine (10/20): Anchored by return on invested capital (ROIC) of -23.4%, gross margin of 54.6%, operating margin of -12.5%, and free cash flow yield of 0.10%.
Whale 13F & Options Flow (5/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (6/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of 2.12, Piotroski F-Score of 6/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

AngioDynamics Inc. (ANGO) is a NASDAQ-listed issuer in the Health Care sector, operating in the Medical/Dental Instruments industry..5B. Per the market data, gross margin is 54.6%, indicating that the company retains a substantial share of revenue after direct costs. — for product lines, customer segments, or specific revenue-generation mechanics beyond the reported revenue figures.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2026-05-31), AngioDynamics Inc. (ANGO) reported $320.2M in annual revenue (up from $292.5M in FY2024, +9.5% YoY) and -$36.7M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($303.9M revenue, -$184.3M net income) through FY2025, ANGO scaled operating cash flow to $3.1M and free cash flow to $508.0K, backed by $269.7M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (D- • RQD 36/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of 0.10% and institutional whale pillar of 5/20. With Fundamental Cash Engine at 10/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $9.39 – $16.29 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -12.5% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

No upstream or downstream dependencies, butterfly links, or proprietary signals are recorded. Sector: Health Care; industry: Medical/Dental Instruments. — for sector correlations or 2nd-order bottlenecks. Investors should note that the absence of mapped links is itself a data gap rather than evidence of independence.

Key Question #1: Can ANGO sustain or expand its -12.5% operating margin and -23.4% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $320.2M and free cash flow of $508.0K, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is ANGO's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ANGO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for AngioDynamics Inc. (ANGO) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ANGO Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance UK • 21h ago

AngioDynamics, Inc. (ANGO) stock price, news, quote and history

Yahoo Finance UK report covering AngioDynamics Inc. (ANGO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The Motley Fool • 1d ago

Why AngioDynamics Crashed Today

The Motley Fool report covering AngioDynamics Inc. (ANGO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Yahoo Finance • 1d ago

AngioDynamics (ANGO) Reports Q1 Loss, Lags Revenue Estimates

Yahoo Finance report covering AngioDynamics Inc. (ANGO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 1d ago

AngioDynamics, Inc. 2027 Q1 - Results - Earnings Call Presentation (NASDAQ:ANGO) 2026-10-08

Seeking Alpha report covering AngioDynamics Inc. (ANGO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Simply Wall St • 1d ago

AngioDynamics (ANGO) Stock Price Sinks As Losses Cloud Med Tech Progress

Simply Wall St report covering AngioDynamics Inc. (ANGO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Investing.com • 1d ago

Canaccord reiterates AngioDynamics stock rating on growth platforms

Investing.com report covering AngioDynamics Inc. (ANGO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE GuruFocus • 1d ago

AngioDynamics (ANGO) Prepares for Earnings Amid Mixed Signals on Valuation and Insider Activity

GuruFocus report covering AngioDynamics Inc. (ANGO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

A pancreatic cancer study linked an electrical-pulse approach to 28 months’ median survival versus 15.

Stock Titan report covering AngioDynamics Inc. (ANGO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ANGO Bull vs. Bear Conversation Board — What's Your Call at $11.76?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ANGO 🐻 33% BEARISH CONVICTION

CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $14.15 (+18.0%)

📌 Pinned Debate

Revenue grew from $292.5M in FY 2024 to $320.2M in FY 2025 and the company posted a 54.6% gross margin.

Here is why I am bullish on ANGO here at $11.99: Revenue grew from $292.5M in FY 2024 to $320.2M in FY 2025 and the company posted a 54.6% gross margin.. Compare ANGO's -12.5% operating margin and -23.4% ROIC against the rest of Medical/Dental Instruments. As long as cash conversion holds up, dips toward $11.39 are getting bought.

EarningsSniper 🐂 BULL

Both sides have a point here — ANGO's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $9.23 (-23.0%)

Spot @ $11.99

ROIC of -23.4% and a 0.1% FCF yield indicate the business is not currently generating returns on invested capital.

ROIC of -23.4% and a 0.1% FCF yield indicate the business is not currently generating returns on invested capital.. Look at the math on ANGO: paying current EV/EBITDA multiples for -23.4% ROIC and -12.5% operating margins leaves zero margin of safety if Medical/Dental Instruments demand softens. I'd wait for a retest of $10.55 before getting long.